Rising Swiss rivalry as Roche and Novartis target same diseases

ZURICH (Reuters) - Swiss drugmakers Roche and Novartis released data on Wednesday on treatments aimed at winning sales from each other in eye disease and multiple sclerosis, in a sign of rising rivalry.Facing each other across the Rhine in Basel, the drugmakers have clashed and cooperated over the years, but their latest products point to more direct competition.Roche Chief Executive Severin Schwan is looking beyond cancer drugs to fresh treatment areas, while Novartis CEO Vas Narashiman bulks..